Clinical Trials
92 trialsPlatinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy
Eastern Cooperative Oncology Group
Cisplatin vs. Doxorubicin/Cyclophosphamide in BrCa
Beth Israel Deaconess Medical Center
Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases
National Cancer Institute (NCI)
Chemotherapy and Stem Cell Transplantation in Treating Patients With Stage IIIB Breast Cancer
City of Hope Medical Center
Bortezomib Followed by Pembrolizumab and Cisplatin in metTNBC
Baylor Research Institute
SOLARA
Hoosier Cancer Research Network
Cisplatin Plus Romidepsin & Nivolumab in Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC)
University of Kansas Medical Center
A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors
Eli Lilly and Company
BOCIS
Sun Yat-sen University
SAFIR02_Breast
UNICANCER
IVY
Eli Lilly and Company
PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations
Hoosier Cancer Research Network
First-line Gemcitabine Plus Cisplatin in Locally Advanced (IIIC Stage) Breast Cancer Patients
The National Center of Oncology, Azerbaijan
NeoURANIA
RenJi Hospital
A Phase II Study of Triple-negative Breast Cancer Brain Metastases.
Fudan University
APP
RenJi Hospital
First-line Nab-paclitaxel Plus Cisplatin Plus Carilizumab in mTNBC Patients
Fudan University
Adding Adjuvant Cisplatin and Gemicitabine Versus Capecitabine in Triple-negative Breast Cancer Patients in Non pCR After Neoadjuvant Standard Chemotherapy
Assiut University
TA(E)C-GP Versus A(E)C-T for the High Risk TNBC Patients and Validation of the mRNA-lncRNA Signature
Fudan University
Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors
Emory University
Vinorelbine, Cisplatin, Disulfiram and Copper in CTC_EMT Positive Refractory Metastatic Breast Cancer.
National Cancer Institute, Slovakia
Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)
Incyte Corporation
TNBC
Fudan University
TNBC
Fudan University
A Study of LY3023414 in Participants With Advanced Cancer
Eli Lilly and Company
TONIC
The Netherlands Cancer Institute
TONIC-2
The Netherlands Cancer Institute
Safety and Efficacy of Toripalimab in HER2- Metastatic Breast Cancer Patients Treated With Metronomic Vinorelbine
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
INVINCIBLE TRIAL: Intratumoral INT230-6 in Breast Cancer
Ottawa Hospital Research Institute
Cisplatin + RT for Triple Negative Breast Cancer
Dana-Farber Cancer Institute
Apatinib in Neoadjuvant Therapy for Patients With Breast Cancer
Hebei Medical University Fourth Hospital
Preoperative Cisplatin and Bevacizumab in ER-, PR-, HER2 Negative Breast Cancer
Massachusetts General Hospital
A-Plus
National Taiwan University Hospital
GEP
Fudan University
Repeated Bone Marrow Transplantation in Treating Women With Advanced Breast Cancer
Louisiana State University Health Sciences Center Shreveport
High Dose Chemotherapy Plus Peripheral Stem Cell Transplantation Compared With Standard Therapy in Treating Women With Metastatic or Recurrent Breast Cancer
Canadian Cancer Trials Group
A Study of Prexasertib (LY2606368) With Chemotherapy or Targeted Agents in Participants With Advanced Cancer
Eli Lilly and Company
A Drug-Interaction Study of Necitumumab (IMC-11F8) in Combination With Gemcitabine-Cisplatin
Eli Lilly and Company
Effect of Pembrolizumab and Cisplatin on Metastatic, Locally Recurrent or Inoperable Triple-Negative Breast Cancer
University of Washington
Filgrastim Plus Chemotherapy Compared With Filgrastim Alone In Treating Women Undergoing Peripheral Stem Cell Transplantation For Breast Cancer
M.D. Anderson Cancer Center
Cisplatin, Paclitaxel, and Everolimus in Treating Patients With Metastatic Breast Cancer
Vanderbilt-Ingram Cancer Center
Phase II Pilot Study Assessing Efficacy of a Cisplatin - Metronomic Cyclophosphamide Treatment in Patients With Metastatic Triple Negative Breast Cancer Resistant to Anthracyclines and Taxanes
Centre Jean Perrin
Chemotherapy and Peripheral Stem Cell Transplantation Followed by Trastuzumab in Treating Women With Metastatic Breast Cancer
Dana-Farber Cancer Institute
Brostallicin and Cisplatin in Treating Patients With Metastatic Breast Cancer
Alliance for Clinical Trials in Oncology
The Maintenance Regimen and Revised Regimen for Advanced Breast Cancer Survivors After First-line Salvage Therapy
Shandong Cancer Hospital and Institute
Gemcitabine/ Trastuzumab and Gemcitabine/ Cisplatin/ Trastuzumab in Patients With Metastatic Breast Cancer
Ohio State University Comprehensive Cancer Center
Study of Temsirolimus, Erlotinib and Cisplatin in Solid Tumors
Columbia University
Sorafenib, Pemetrexed, and Cisplatin in Treating Patients With Advanced Solid Tumors
Masonic Cancer Center, University of Minnesota
Phase Ib/II Trials of RAD001 in Triple Negative Metastatic Breast Cancer
National Cancer Center, Korea